| Myasthenia Gravis, Generalized
Rystiggo vs Ultomiris
Side-by-side clinical, coverage, and cost comparison for myasthenia gravis, generalized.Deep comparison between: Rystiggo vs Ultomiris with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUltomiris has a higher rate of injection site reactions vs Rystiggo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ultomiris but not Rystiggo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rystiggo
Ultomiris
At A Glance
SC injection
Once weekly (6-week cycles)
FcRn blocker
IV infusion
Every 4-8 weeks
C5 complement inhibitor
Indications
- Myasthenia Gravis, Generalized
- Paroxysmal nocturnal hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Myasthenia Gravis, Generalized
- Neuromyelitis Optica
Dosing
Myasthenia Gravis, Generalized Weight-based SC infusion once weekly for 6 weeks: less than 50 kg: 420 mg (3 mL); 50 to less than 100 kg: 560 mg (4 mL); 100 kg and above: 840 mg (6 mL); administer at up to 20 mL/hour; subsequent cycles based on clinical evaluation, no sooner than 63 days from start of previous cycle.
Paroxysmal nocturnal hemoglobinuria, Atypical Hemolytic Uremic Syndrome (5 to <40 kg) Weight-based IV loading dose (600-1,200 mg), followed by weight-based maintenance dose every 4 weeks (5 to <20 kg) or every 8 weeks (20 to <40 kg), starting 2 weeks after loading dose.
Paroxysmal nocturnal hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized, Neuromyelitis Optica (>=40 kg) Weight-based IV loading dose (2,400-3,000 mg), followed by weight-based maintenance dose (3,000-3,600 mg) every 8 weeks, starting 2 weeks after loading dose.
Contraindications
—
- Unresolved serious Neisseria meningitidis infection
Adverse Reactions
Most common (>=10%) headache, infections, diarrhea, pyrexia, hypersensitivity reactions, nausea
Serious infections (including fatal pneumonia), aseptic meningitis
Postmarketing herpes zoster
Most common (>=10%) Upper respiratory tract infection, headache, diarrhea, nausea, vomiting, hypertension, pyrexia, back pain, arthralgia, COVID-19
Serious Meningococcal infections, other infections (including fatal COVID-19 pneumonia and sepsis), infusion-related reactions
Postmarketing Anaphylaxis, cholestatic or mixed pattern liver injury with increased serum liver enzymes and bilirubin
Pharmacology
FcRn antagonist; rozanolixizumab-noli is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor (FcRn), reducing circulating IgG levels and pathogenic AChR and MuSK autoantibody concentrations in patients with generalized myasthenia gravis.
Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds complement protein C5 with high affinity, preventing its cleavage to C5a (proinflammatory anaphylatoxin) and C5b (initiating subunit of the membrane attack complex), thereby inhibiting MAC formation and terminal complement-mediated tissue damage in PNH, aHUS, gMG, and NMOSD.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rystiggo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Ultomiris
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
UnitedHealthcare
Rystiggo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Ultomiris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Rystiggo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Ultomiris
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Myasthenia Gravis - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Ultomiris.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RystiggoView full Rystiggo profile
UltomirisView full Ultomiris profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.